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Abstract— Abietane-type diterpenoids, either naturally occurring or synthetic, have shown a wide range of pharmacological actions, 
including antiprotozoal properties. In this study, we report on the antileishmanial evaluation of a series of (+)-dehydroabietylamine 
derivatives functionalized at C7 and/or C12. Thus, the activity in vitro against Leishmania infantum, Leishmania donovani, Leishmania 
amazonensis and Leishmania guyanensis, was studied. Most of the benzamide derivatives showed activities at low micromolar 
concentration against cultured promastigotes of Leishmania spp. (IC50 = 2.2-46.8 µM), without cytotoxicity on J774 macrophage cells. 
Compound 15, an acetamide, was found to be the most active leishmanicidal agent, though it presented some cytotoxicity on J774 cells. 
Among the benzamide derivatives, compounds 8 and 10, were also active against L. infantum intracellular amastigotes, being 18- and 23-
fold more potent than the reference compound miltefosine, respectively. Some structure-activity relationships have been identified for the 
antileishmanial activity in these dehydroabietylamine derivatives. © 2017 Elsevier Science. All rights reserved 
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Introduction 
Leishmaniasis is a poverty-associated disease caused by 
more than 20 species of protozoan parasites of the genus 
Leishmania. It is a wide spectrum of vector born diseases 
with great epidemiological and clinical diversity. Three 
major clinical forms of the disease are visceral, cutaneous, 
and mucocutaneous leishmaniasis, which differ in 
immunopathologies and degree of morbidity and mortality. 
Visceral leishmaniasis (VL, also known as Kala-azar) is the 
most severe form, fatal, if it is not treated. Moreover, VL 
has emerged as an important opportunistic infection 
associated with HIV and co-infection is becoming an 
increasing problem that requires urgent attention [1]. 
Administration of pentavalent antimonials remains as the 
first choice therapy, followed by amphotericin B and 
miltefosine. However, the growing incidence of parasitic 
resistance, the route of administration, long-term 
treatments, high toxicity and the drug cost makes the 
development of new drugs necessary [2].  
Natural products are potential sources of new and selective 
agents for the treatment of a number of diseases, including 
those caused by parasites. To date, many compounds from 
plant sources have shown potential antileishmanial activity, 
though none of them has undergone clinical evaluation [3]. 
Among these, some naturally occurring abietane-type 
diterpenoids and semisynthetic derivatives have shown 
promising antiparasitic activities [4]. For example, 
ferruginol (1), isolated from Juniperus procera, showed 
good antileishmanial activity (IC50 = 12.2 µM) against 
Leishmania donovani promastigotes and 12-
methoxycarnosic acid (2) (Fig. 1), isolated from Salvia 
repens, showed potent activity (IC50 = 0.75 µM) against 
axenic L. donovani amastigotes [5,6]. On the other hand, 
semisynthetic ferruginol analogues 3 (Fig. 1) displayed 
antileishmanial activity (IC50= 22.3-35.0 µM) on 
intracellular amastigotes (L. infantum and L. braziliensis), 
being more active and less toxic than the reference drug 
glucantime [7]. Recently, Moreira et al. reported on the 
antileishmanial activity of some dehydroabietic acid 
derivatives (e.g. cyclohexyl-L alanine derivative 4, Fig. 1) 




and some dehydroabietylamine amides (e.g. acrylic acid 
derivative 5, Fig. 1), which were able to kill intracellular L. 
donovani amastigotes in the range 0.4 to 9.0 µM [8]. 
 
 
The present study is a continuation of our research 
programs to synthesize and discover bioactive diterpenoids 
[9]. It includes the synthesis of several amide derivatives 
from commercially available (+)-dehydroabietylamine (6, 
Scheme 1) with potential antileishmanial activity. Among 
these derivatives, several nitroaromatic compounds were 
envisaged as antileishmanial prodrugs, as it is known that 
these compounds require activation before exerting their 
therapeutic effects [10]. Herein, we describe the 
antileishmanial activity of dehydroabietylamine derivatives 
(7-15) (Scheme 1) against Leishmania infantum, L. 
donovani, L. amazonensis and L. guyanensis. Our aim is to 
identify new antileishmanial drug leads and their structure-
activity relationships on modifying the functionalization 
present at C7, C12 and C18. 
 
 
Results and Discussion 
Chemistry 
 The compounds 7-15 were synthesized from (+)-
dehydroabietylamine (6), as shown in Scheme 1. 
Compounds 13 and 15 are novel derivatives. 
 Benzamides 7, 8 and 10 were obtained following similar 
conditions to those reported in the literature [11]. Thus, 
compound 7 (N-benzoyldehydroabietylamine) was 
synthesized by acylation of dehydroabietylamine (6) with 
benzoyl chloride in high yield (87%).  Then, benzamide 7 
was subjected to nitration at C-12 with acetic anhydride-
cupric nitrate to give nitroderivative 8 (66% yield), while 
benzylic oxidation with CrO3 gave ketone 10 in 48% yield. 
Similar benzylic oxidation at C-7 of nitroderivative 8 gave 
benzamide 9 in 40% yield. A similar synthetic sequence 
using acetyl chloride as acylating agent of 6 instead of 
benzoyl chloride, afforded the corresponding acetamides 
11-14 in reasonable yields. Finally, compound 15 was 
obtained by Fischer indole reaction of 14 with a fluorinated 
phenylhydrazine [12].  
 
Biological Evaluation 
 Compounds 6-15 (Scheme 1) were evaluated for 
antileishmanial activity against four different Leishmania 
species (L. infantum, L. donovani, L. amazonensis and L. 
guyanensis), as well as for cytotoxicity against J774 
macrophages, following established procedures (see 
Experimental section). The results on extracellular forms 
(promastigotes) are summarized in Table 1. 
 
 As can be seen in Table 1, compounds (benzamides) 7-
10 showed relevant activity without significant cytotoxicity 
on J774 macrophage cells (CC50 > 200 µM), being L. 
donovani the most sensitive species. Compound 15, an 
acetamide, was found to be the most active leishmanicidal 
agent, though it presented some cytotoxicity on J774 cells. 
The remaining acetamides, compounds 11-14, also 




Figure 1. Examples of antileishmanial abietane diterpenoids. 
 
Scheme 1. Synthesis of the tested compounds 7-15. 
 




Table 1. IC50 Leishmanicidal and cytotoxic effects (in µM) of C7- and C12-functionalized dehydroabietylamine derivatives 
on in vitro promastigote assay. 
a IC50, concentration of the compound that produced a 50% reduction in parasites; SD: standard deviation. b Selectivity index, 
SI = CC50/IC50. c CC50, concentration of the compound that produced a 50% reduction of cell viability in treated culture cells 
with respect to untreated ones. d IC50 values obtained from six data points instead of eight. The two points removed because 
of problems solubility corresponded to the more concentrated dilutions 100 and 50 µg/mL of test compound. e ND, not 
determined. 
 
It is interesting to note that benzamides 7-10 showed better 
activity against L. amazonensis parasites compared to the 
standard drug miltefosine, used as reference. They also 
showed better selectivity index (SI = CC50/IC50) in this 
Leishmania spp. In general, L. guyanensis was the least 
sensitive parasite strain to the tested compounds. 
Unfortunately, the tested acetamide derivatives displayed 
toxicity against the J774 cell line. On the contrary, the 
benzamide derivatives showed no cytotoxicity at 200 µM. 
 In the mammalian hosts Leishmania parasites exist as 
intracellular amastigotes within phagolysosomes of 
macrophages. Therefore, benzamides 7-10, which are the 
most active compounds in the antipromastigote assay (SI 
from >2 to >90), could be good candidates for subsequent 
investigations against the clinically relevant Leishmania 
amastigote forms. Consequently, these benzamides were 
tested against L. infantum and L. amazonensis intracellular 
amastigotes (Table 2). 
 When the assay was carried out on L. infantum 
amastigotes, the antileishmanial activity of the tested 
derivatives was similar in comparison to extracellular 
forms. However, L. amazonensis amastigotes were more 
sensitive to these compounds. Compound 10 was the most 
potent for both parasite strains (IC50 = 2.5 and 3.0 µM, 
respectively). 
 Different authors have claimed that a compound should 
have a selectivity index (SI) value > 20 to be considered to 
possess leishmanicidal properties [13]. This requirement is 
satisfied by compounds 7-10 against L. infantum and L. 
amazonensis, except compound 9 against L. infantum. 
Table 2. IC50 Leishmanicidal and cytotoxic effects (in µM) of C7- and C12-functionalized dehydroabietylamine derivatives 











a IC50, concentration of the compound that produced a 50% reduction in parasites; SD: standard deviation. b Selectivity index, 
SI = CC50/IC50. c CC50, concentration of the compound that produced a 50% reduction of cell viability in treated culture cells 
with respect to untreated ones. d IC50 values obtained from six data points instead of eight. The two points removed because 
of problems solubility corresponded to the more concentrated dilutions 100 and 50 µg/mL of test compound.
Compound 
L. infantum L. donovani L. amazonensis L. guyanensis Macrophages J774 
IC50a±SD   SI b IC50±SD   SI IC50±SD   SI IC50±SD   SI CC50c 
6 - - - - - - - - 14,5± 1,6 
7d     3,1±0,2 >64     2,2±0,2 >90    3,7±0,2     >54     20,4± 5,7 >10 >200 
8 11,1±0,8 >18 3,2± 0,1 >62 20,7± 0,5 >10 94,5± 26,1 >2 >200 
9 23,9±1,2 >8 5,4± 0,4 >37 12,2± 2,2 >16 38,5± 1,4 >5 >200 
10 8,7±0,8 >23 4,0± 0,3 >50 4,9± 0,5 >41 8,6± 1,2 >23 >200 
11 - - - - - - - - 21,6± 1,6 
12 - - - - - - - - 13,7± 1,5 
13 - - - - - - - - 39,2± 7,3 
14 - - - - - - - - 72,3± 6,1 
15 1,5±0,1 19,2 2,8± 0,4 10,3 4,0± 0,2 7,2 NDe  28,8± 1,9 
Miltefosine 3,4±0,6 40,1 0,15± 0,02 909 47,7± 5,0 2,9 18,2± 0,6 7,5 136,4± 1,4 
Compound 
  L. infantum   L. amazonensis   Macrophages J774 
       IC50
a  ±SD SIb            IC50 ±SD         SI  CC50
c 
7d  4,7±0,2 > 42  5,0±0,2 > 40  >200 
8  3,3±0,2 > 61  3,5±0,2 > 57  >200 
9  17,5±0,4 > 11  3,7±0,5 > 54  >200 
10  2,5±0,9 > 80  3,0±0,4 > 67  >200 
Miltefosine   58,1±4,4 2,3   16,5±1,9 8,2   136,4 




The resultant data indicates that the introduction of a nitro 
group at C-12 or a carbonyl group at C-7 increases the 
antileishmanial activity. In the case of L. infantum 
amastigotes both modifications on the parent molecule led 
to lower activity.  
Conclusions 
 In summary, a study of antileishmanial activity of 
several dehydroabietylamine derivatives has been carried 
out in vitro. Particular modifications of the molecular 
scaffold abieta-8,11,13-triene functionalized at C-7, C-12, 
and C-18 have led to potent antileishmanial agents. Two 
benzamide derivatives, compounds 8 and 10, were found to 
consistently reduce parasitimia at low micromolar 
concentrations. The presence of a benzamide at C-18 and a 
carbonyl group at C-7 in the molecule, compound 10, 
resulted in the highest antileishmanial activity and 
selectivity index against L. infantum amastigotes (IC50 = 
2.5 µM, SI > 80). Moreover, the activity of compound 10 
was remarkable, as it was more potent than the reference 
drug miltefosine, and showed good selectivity. Thus, the 
abietane-type diterpenoids are promising scaffolds for the 
development of treatments for Leishmaniasis. 
Experimental 
General. 
See supporting information. 
Chemistry. 
Materials. Compounds 7-15 have been prepared following 
similar conditions of reported procedures [11, 12]. All 
compounds prepared in this work exhibit spectroscopic 
data in agreement with the proposed structures. Purity of all 
final compounds was 95% or higher. 
N-benzoyl-dehydroabietylamine (7). To a solution of 
dehydroabietylamine (6) (2.0 g, 7 mmol) and triethylamine 
(2.0 mL, 14 mmol) in THF (35 mL) at 0 ºC, benzoyl 
chloride (0.9 mL, 7.7 mmol) was added dropwise. Then, it 
was allowed to warm to rt and stirred overnight (16 h). The 
resulting reaction mixture was treated with 1 M HCl (20 
mL), phases separated, and the aqueous phase was 
extracted twice with ethyl acetate. The combined organic 
extracts were washed with brine, dried over Na2SO4 and 
concentrated. The resulting residue was purified by flash 
chromatography, using DCM as eluent, to give benzamide 
7 (2.44 g, 87%) as a white solid: [α]20D +2.7 (c 3.0, CHCl3); 
1H NMR (300 MHz) δ  7.75-7.70 (2H, m), 7.52-7.39 (3H, 
m), 7.17 (1H, d, J = 8.5), 7.00 (1H, dd, J = 8.5, 1.5), 6.90 
(1H, br s), 6.16 (1H, t, J = 6.0), 3.44 (1H, dd, J = 15.0, 6.0), 
3.35 (1H, dd, J = 15.0, 6.0), 2.31 (1H, br d, J = 12.0), 1.25 
(3H, s), 1.22 (6H, d, J = 6.5), 1.02 (3H, s); 13C NMR (75 
MHz) δC 167.6 (s), 147.0 (s), 145.6 (s), 134.7 (s), 131.3 (s), 
128.6 x 2 (d), 126.9 (d), 126.8 x 2 (d), 124.2 (d), 123.8 (d), 
50.3 (t), 45.8 (d), 38.3 (t), 37.6 (s), 37.5 (s), 36.4 (t), 33.4 
(d), 30.4 (t), 25.4 (q), 23.9 (q), 23.9 (q), 19.1 (t), 18.8 (q), 
18.6 (t); HRMS (ESI) m/z 390.2825 [M+H]+, calcd for 
C27H36NO: 390.2797. The NMR and MS data agree with 
those reported in the literature [8b, 11]. 
N-benzoyl-12-nitrodehydroabietylamine (8). Powdered 
cupric nitrate trihydrate (2.20 g, 9.0 mmol) was added in 
portions to a stirred solution of benzamide 7 (1.74 g, 4.47 
mmol) in acetic anhydride (70 mL) and the blue solution 
was stirred at 5 ºC for 48 h. Then, the mixture was poured 
into water with stirring and the resulting precipitate was 
filtered off, washed with water and crystallized from 
methanol to give the nitro derivative 8 (1.28 g, 66%) as a 
pale yellow solid: [α]20D +24.2 (c 3.0, CHCl3); 1H NMR 
(300 MHz) δ  7.75-7.70 (2H, m), 7.62 (1H, s), 7.52-7.39 
(3H, m), 7.06 (1H, s), 6.18 (1H, m), 3.56 (1H, dd, J = 15.0, 
6.0), 3.20 (1H, dd, J = 15.0, 6.0), 2.29 (1H, br d, J = 12.0), 
1.27-1.19 (9H, m),  1.01 (3H, m); 13C NMR (75 MHz) δC 
167.7 (s), 149.0 (s), 148.3 (s), 141.0 (s), 139.5 (s), 134.8 
(s), 131.5 (d), 128.6 x 2 (d), 127.9 (d), 126.2 x 2 (d), 120.3 
(d), 50.2 (t), 45.1 (d), 38.3 (t), 37.7 (s), 37.6 (s), 36.3 (t), 
30.2 (t), 28.7 (d), 25.3 (q), 2 x 23.5 (q), 18.7 (t), 18.6 (q), 
18.4 (t); HRMS (ESI) m/z 435.2739 [M+H]+, calcd for 
C27H35N2O3: 435.2648. The NMR and MS data agree with 
those reported in the literature [11]. 
N-benzoyl-12-nitrodehydroabietylamine-7-one (9). A 
solution of CrO3 (500 mg, 5.0 mmol) in 25 mL of acetic 
acid was added dropwise to a solution of nitro-benzamide 8 
(1.1 g, 2.50 mmol) in 10 mL of acetic acid. The mixture 
was stirred at room temperature for one hour and heated at 
60 ºC for 17 h. Then, the mixture was poured into water 
and ice, and extracted with chloroform. The combined 
organic extracts were washed with brine, dried over 
Na2SO4 and concentrated. The resulting crude was purified 
by flash chromatography, using hexane-ethyl acetate (6:4) 
as eluent, to give ketone 9 (455 mg, 40%) as a yellowish 
foam: [α]20D +16.9 (c 1.3, CHCl3); 1H NMR (300 MHz) δ  
8.08 (1H, s), 7.75-7.70 (2H, m), 7.59 (1H, s), 7.52-7.35 
(3H, m), 6.19 (1H, m), 3.35 (1H, m), 3.25 (1H, m), 2.32 
(1H, br d, J = 12.0), 1.30-1.19 (9H, m),  1.10 (3H, m); 13C 
NMR (75 MHz) δC 197.2 (s), 167.9 (s), 154.0 (s), 153.0 (s), 
140.0 (s), 134.8 (s), 133.0 (s), 131.6 (d), 128.6 x 2 (d), 
127.4 (d), 126.8 x 2 (d), 119.1 (d), 49.7 (t), 44.4 (d), 37.9 
(s), 37.9 (s), 37.2 (t), 36.0 (t), 35.9 (t), 28.4 (d), 23.9 (q), 2 
x 23.4 (q), 18.4 (q), 17.9 (t); HRMS (ESI) m/z 449.2463 
[M+H]+, calcd for C27H33N2O4: 449.2440. 
N-benzoyl-dehydroabietylamine-7-one (10). A solution 
of CrO3 (0.36 g, 3.6 mmol) in 20 mL of acetic acid was 
added dropwise to a solution of benzamide 7 (700 mg, 1.8 
mmol) in 10 mL of acetic acid. The mixture was stirred at 
room temperature for one hour and heated at 60 ºC for 17 h. 
Then, the mixture was poured into water and ice, and 
extracted with chloroform. The combined organic extracts 
were washed with brine, dried over Na2SO4 and 
concentrated. The resulting yellowish crude oil was 
purified by flash chromatography, using petroleum ether-
acetone (3:1) as eluent, to give ketone 10 (350 mg, 48%) as 
a yellowish foam: [α]20D -22.1 (c 2.8, CHCl3); 1H NMR 
(300 MHz) δ  7.82-7.83 (1H, m), 7.75-7.70 (2H, m), 7.49-




7.27 (5H, m), 6.40 (1H, br s), 3.52 (1H, dd, J = 15.0, 6.0), 
3.20 (1H, dd, J = 15.0, 6.0), 3.00-2.72 (3H, m), 2.34 (1H, 
br d, J = 12.0), 1.28 (3H, s), 1.23-1.20 (6H, m), 1.09 (3H, 
s); 13C NMR (75 MHz) δC 199.3 (s), 168.0 (s), 153.4 (s), 
146.8 (s), 134.6 (s), 132.7 (d), 131.4 (d), 130.1 (s), 128.5 x 
2 (d), 126.9 x 2 (d), 125.0 (d), 123.6 (d), 49.6 (t), 44.7 (d), 
37.9 (s), 37.8 (s), 37.4 (t), 36.0 (t), 35.9 (t), 33.5 (d), 23.9 
(q), 23.7 (q), 23.7 (q), 18.5 (q), 18.2 (t); HRMS (ESI) m/z 
404.2634 [M+H]+, calcd for C27H34NO2: 404.2590. The 
NMR and MS data agree with those reported in the 
literature [11]. 
N-acetyl-dehydroabietylamine (11). To a solution of 
dehydroabietylamine (6) (1.45 g, 5 mmol) and 
triethylamine (1.4 mL, 10 mmol) in THF (25 mL) at 0 ºC, 
acetyl chloride (0.4 mL, 5.5 mmol) was added dropwise. 
Then, it was allowed to warm to rt and stirred overnight (16 
h). The resulting reaction mixture was treated with 1 M 
HCl (20 mL), phases separated, and the aqueous phase was 
extracted twice with ethyl acetate. The combined organic 
extracts were washed with brine, dried over Na2SO4 and 
concentrated. The resulting yellowish crude oil was 
purified by flash chromatography, using hexane-ethyl 
acetate (4:6) as eluent, to give acetamide 11 (1.59 g, 96%) 
as a yellowish foam: [α]20D +18.2 (c 0.55, CHCl3); 1H 
NMR (300 MHz) δ  7.29 (1H, d, J = 8.5), 7.12 (1H, dd, J = 
8.5, 1.5), 7.02 (1H, br s), 6.89 (1H, t, J = 6.0), 3.40 (1H, dd, 
J = 15.0, 6.0), 3.16 (1H, dd, J = 15.0, 6.0), 2.41 (1H, br d, J 
= 12.0), 2.08 (3H, s), 1.36 (6H, d, J = 6.0), 1.35 (3H, s), 
1.07 (3H, s); 13C NMR (75 MHz) δC 170.2 (s), 146.8 (s), 
145.0 (s), 134.4 (s), 126.5 (d), 123.7 (d), 123.4 (d), 53.1 (s), 
49.6 (t), 44.8 (d), 37.9 (t), 37.0 (s), 35.8 (t), 33.0 (d), 29.8 
(t), 25.0 (q), 23.6 (q), 23.6 (q), 22.7 (q), 18.6 (t), 18.4 (q), 
18.3 (t); HRMS (ESI) m/z 328.2621 [M+H]+, calcd for 
C22H34NO: 328.2640. The NMR and MS data agree with 
those reported in the literature [14]. 
N-acetyl-12-nitrodehydroabietylamine (12). Powdered 
cupric nitrate trihydrate (1.10 g, 4.55 mmol) was added in 
portions to a stirred solution of acetamide 11 (745 mg, 2.27 
mmol) in acetic anhydride (30 mL) and the blue solution 
was stirred at 5 ºC for 17 h. Then, the mixture was poured 
into water and extracted with ethyl acetate. The organic 
extracts were washed with brine, dried over Na2SO4 and 
concentrated. The resulting residue was purified by 
chromatography eluting with hexane-ethyl acetate (4:6) to 
give 0.64 g (76%) of pure nitro derivative 12 as a slightly 
orange foam: [α]20D +45.3 (c 0.75, CHCl3); 1H NMR (300 
MHz) δ  7.62 (1H, s), 7.08 (1H, s), 5.48 (1H, m), 3.48-3.30 
(2H, m), 2.27 (1H, br d, J = 12.0), 1.97 (3H, s), 1.27-1.21 
(9H, m),  0.94 (3H, s); 13C NMR (75 MHz) δC 170.2 (s), 
148.4 (s), 147.6 (s), 141.0 (s), 139.5 (s), 127.9 (d), 120.2 
(d), 49.8 (t), 44.7 (d), 38.1 (t), 37.5 (s), 37.3 (s), 36.0 (t), 
30.0 (t), 28.0 (d), 25.1 (q), 23.6 (q), 23.5 (q), 18.6 (q), 18.6 
(t), 18.3 (q); HRMS (EI) m/z 373.2472 [M+H]+, calcd for 
C22H33N2O3: 373.2491. The NMR and MS data agree with 
those reported in the literature [14]. 
N-acetyl-12-nitrodehydroabietylamine-7-one (13). A 
solution of CrO3 (600 mg, 6.0 mmol) in 28 mL of acetic 
acid was added dropwise to a solution of nitro-acetamide 
12 (1.1 g, 3.0 mmol) in 12 mL of acetic acid. The mixture 
was stirred at room temperature for one hour and heated at 
60 ºC for 17 h. Then, the mixture was poured into water 
and ice, and extracted with chloroform. The combined 
organic extracts were washed with brine, dried over 
Na2SO4 and concentrated. The resulting crude oil was 
purified by flash chromatography, using hexane-ethyl 
acetate (15:85) as eluent, to give ketone 13 (330 mg, 30%) 
as a light orange foam: [α]20D +27.4 (c 5.0, CHCl3); 1H 
NMR (300 MHz) δ  8.05 (1H, s), 7.63 (1H, s), 6.33 (1H, 
m), 3.26 (1H, m), 3.14 (2H, m), 2.34 (1H, br d, J = 12.0), 
1.94 (3H, s), 1.32-1.25 (9H, m),  1.05 (3H, s); 13C NMR 
(75 MHz) δC 197.3 (s), 170.6 (s), 154.1 (s), 152.8 (s), 139.6 
(s), 132.9 (s), 127.0 (d), 119.0 (d), 48.9 (t), 43.5 (d), 37.5 
(s), 37.4 (s), 37.1 (t), 35.7 (t), 35.4 (t), 28.2 (d), 23.6 (q), 
23.2 (q), 23.2 (q), 23.1 (q), 18.3 (q), 17.8 (t); HRMS (EI) 
m/z 387.2245 [M+H]+, calcd for C22H31N2O4: 387.2284. 
N-acetyl-dehydroabietylamine-7-one (14). A solution of 
CrO3 (0.45 g, 4.5 mmol) in 20 mL of acetic acid was added 
dropwise to a solution of acetamide 11 (740 mg, 2.2 mmol) 
in 10 mL of acetic acid. The mixture was stirred at room 
temperature for one hour and heated at 60 ºC for 17 h. 
Then, the mixture was poured into water and ice, and 
extracted with chloroform. The combined organic extracts 
were washed with brine, dried over Na2SO4 and 
concentrated. The resulting yellowish crude oil was 
purified by flash chromatography, using hexane-ethyl 
acetate (4:6 to 3:7) as eluent, to give ketone 14 (565 mg, 
73%) as a yellowish oil: [α]20D -26.7 (c 0.6, CHCl3); 1H 
NMR (300 MHz) δ  7.70 (1H, d, J = 2.0), 7.38 (1H, dd, J = 
8.5, 2.0), 7.31 (1H, d, J = 8.5), 6.64 (1H, t, J = 6.0), 3.33 
(1H, dd, J = 15.0, 6.0), 3.00 (1H, dd, J = 15.0, 6.0), 2.36 
(1H, br d, J = 12.0), 1.95 (3H, s), 1.27 (3H, s), 1.19 (6H, d, 
J = 6.0), 1.04 (3H, s); 13C NMR (75 MHz) δC 199.3 (s), 
170.7 (s), 153.5 (s), 146.4 (s), 132.6 (d), 130.2 (s), 124.5 
(d), 123.6 (d), 48.7 (t), 43.7 (d), 2 x 37.5(s), 37.4 (t), 35.8 
(t), 35.5 (t), 33.3 (d), 2 x 23.6 (q), 23.5 (q), 23.1 (q), 18.5 
(q), 18.1 (t); HRMS (ESI) m/z 342.2417 [M+H]+, calcd for 
C22H32NO2: 342.2433. The NMR and MS data agree with 
those reported in the literature [15]. 
N-(((1R,4aS,13cR)-12-fluoro-7-isopropyl-1,4a-dimethyl-
2,3,4,4a,9,13c-hexahydro-1H-dibenzo[a,c]carbazol-1-
yl)methyl)acetamide (15). It was followed a method 
reported in the literature [12]. To a solution of 4-
fluoroaniline (50 mmol) in 50 ml of 20% HCl was added 
dropwise the solution of NaNO2 (3.63 g, 52.5 mmol) in 8 
ml of water while cooling with an ice-water bath. The 
reaction mixture was stirred at 0 ºC for 1 h to give a clear 
solution. Then to the solution was added dropwise a 
solution of SnCl2 (19 g, 0.1 mol) in 30 ml of 35% HCl at 0 
ºC. Then, the mixture was stirred at room temperature for 
1-2 h. The solid product was filtered, washed with 35% 
HCl for 3 times and dried in a vacuum desiccator 
containing phosphorous pentoxide. The product (7 g) could 
be used in subsequent reactions without further 
purification. 




To a solution of ketone-acetamide (14) (190 mg, 0.56 
mmol) in EtOH (2 mL) was added the above prepared 
phenylhydrazine hydrochloride (200 mg, 1.21 mmol) and 
36% HCl (0.2 mL). The mixture was refluxed for 3 h, 
water/ice added and extracted with DCM. The combined 
organic extracts were washed with saturated NaHCO3, 
brine, dried over Na2SO4 and concentrated. The resulting 
brown crude oil was purified by flash chromatography, 
using DCM-MeOH (95:5) as eluent, to give carbazole 15 
(77 mg, 32%) as a dark orange oil: [α]20D 0 (c 3.5, CHCl3); 
1H NMR (300 MHz) δ  9.38 (1H, s, NH), 7.73 (1H, dd, J = 
11.0, 2.0), 7.39 (1H, d, J = 1.5), 7.34 (1H, dd, J = 8.5, 5.0), 
7.27 (1H, d, J = 8.5), 7.16 (1H, dd, J = 8.5, 1.5), 6.90 (1H, 
dt, J = 8.5, 2.0), 5.76 (1H, t, J = 6.0), 4.15 (1H, dd, J = 
15.0, 6.0), 3.16 (1H, dd, J = 15.0, 6.0), 2.28 (1H, br d, J = 
12.0), 1.99 (3H, s), 1.45 (3H, s), 1.30-1.25 (6H, m), 0.99 
(3H, s); 13C NMR (75 MHz) δC 170.7 (s), 157.0 (d, JC,F = 
235), 146.7 (s), 146.7 (s), 136.9 (s), 133.9 (s), 126.7 (s), 
126.2 (d), 123.9 (d, JC,F = 20), 123.5 (d), 119.3 (d), 111.6 
(d, JC,F = 10), 111.0 (d, JC,F = 5), 109.0 (d, JC,F = 25), 107.7 
(d, JC,F = 25), 53.4 (s), 51.3 (t), 48.8 (d), 39.9 (s), 37.2 (t), 
36.4 (t), 33.7 (d), 23.9 (q), 23.9 (q), 23.4 (q), 21.3 (q), 19.6 





Parasites and culture procedure 
The following species of Leishmania were used: L. 
donovani (MHOM/IN/80/DD8) was purchased (ATCC, 
USA), an autochthonous isolate of L. infantum 
(MCAN/ES/96/BCN150) obtained from an asymptomatic 
dog from the Priorat region (Catalunya, Spain), kindly 
given by Prof. Montserrat Portús (Universidad de 
Barcelona); L. amazonensis (MHOM/Br/79/Maria) and L. 
guyanensis 141/93 were kindly provided by Prof. Alfredo 
Toraño (Instituto de Salud Carlos III, Madrid). 
Promastigotes were cultured in Schneider's Insect Medium 
supplemented with 10% heat-inactivated Foetal Bovine 
Serum (FBS) and 1000 U/L of penicillin plus 100 mg/L of 
streptomycin in 25 mL culture flasks at 26 °C. 
 
Promastigote assay 
The activity of functionalized dehydroabietylamine amide 
derivatives on Leishmania promastigotes was performed 
according to the method previously reported by us [16]. 
Parasites (2.5×105 promastigotes/well) were cultured in 96-
well flat-bottom plates. Stock solutions of the tested 
compounds were solubilized at 100 mg/mL in DMSO. 
Serial dilutions 1:2 of test compounds in fresh culture 
medium were performed (100, 50, 25, 12.5, 6.25, 3.12, 1.56 
and 0.78 µg/mL) in a final volume of 200 µL; the solutions 
then were added to the parasites suspension. After an 
incubation period of 48 h at 26 °C, a volume of 20 μL of 
2.5 mM resazurin solution in PBS was added and the plates 
were incubated 3 h under the same conditions. Finally, the 
Relative Fluorescence Units (RFU) (535ex – 590em nm 
wavelength) was determined in a fluorimeter (Infinite 200 
Tecan i-Control). Growth inhibition (%) was calculated by 
100 - [(RFU treated wells – RFU signal-to-noise)/(RFU 
untreated – RFU signal-to-noise) x 100]. All tests were 
carried out in triplicate and the IC50 was calculated by 
probit analysis using SPSS 17.0 Statistics Software. 
Miltefosine (Sigma) was used as reference drug and all 
tests were carried out in triplicate. 
Intracellular amastigote assay 
We performed on L. amazonensis and L. infantum 
according to the novel fluorometric method reported by us 
[17]. To carry out the in vitro macrophage infections, 5x104 
cells were cultured in RPMI-1640 medium and then were 
infected with 5x105 promastigotes. In L. infantum assays, 
the plates were incubated during 48 h at 37 °C, while in L. 
amazonensis assays, were incubated at 33 °C the first 24 h 
and then the temperature was increased to 37 °C for the 
next 24 h. After, the culture medium was removed and the 
cells were washed with buffered RPMI-HEPES at pH 7.4 
for several times in order to eliminate the non-internalized 
promastigotes. One hundred microliters of fresh medium 
tempered at 37 °C was added to the infected cells, which 
then were exposed to 100 µL of test compounds in RPMI-
1640 at different concentrations (100, 50, 25, 12.5, 6.25, 
3.12, 1.56, 0.78 µg/mL in a final volume 200 µL) for 48 h 
at 37 °C. The culture medium was removed by 
centrifugation at 3500 rpm for 5 min (Centrifuge 5403 
Eppendorf) and a lysis solution (0.02 % sodium dodecyl 
sulphate in RPMI-HEPES) was added. After 20 min, the 
treated cells were harvested (centrifugation at 3,500 rpm 
for 5 min at 4° C) and the supernatants were replaced by 
200 μL of fresh Schneider´s culture medium. The plates 
were then incubated at 26 °C for other 3 days to allow the 
transformation of viable amastigotes into promastigotes and 
proliferation. Afterwards, 20 μL/well of 2.5 mM resazurin 
was added and incubated for another 3 h. Finally, URF was 
measured and IC50 was estimated as described above. All 




J774 murine macrophages were grown in RPMI-1640 
medium (Sigma) supplemented with 10 % heat-inactivated 
FBS (30 min at 56 °C), penicillin G (100 U/mL) and 
streptomycin (100 μg/mL). Cell cultures were maintained 
in a humidified 5% CO2/95 % air atmosphere at 37 °C. 
Cells in the pre-confluence phase were harvested 
mechanically to accomplish the assays.  
Cytotoxicity Assay 
The assay was carried out according our methods 
previously described by us [18]. J774 macrophages cell 
lines were seeded (5×104 cells/well) in 96-well flat-bottom 
plates with 100 μL of RPMI 1640 medium. The cells were 
allowed to attach for 2 h at 37 °C, 5% CO2, and then was 
added 100 μL of RPMI-1640 medium with test compound 
at different concentrations (100, 50, 25, 12.5, 6.25, 3.12, 
1.56 and 0.78 µg/mL to the final volume) and exposed for 




another 48 h. Growth controls and signal-to-noise were also 
included. Afterwards, a volume of 20 μL of 2.5 mM 
resazurin solution in PBS was added, and plates were 
returned to the incubator for another 3 h to evaluate cell 
viability. The reduction of resazurin was determined by 
fluorometry as in the promastigote assay. Each 
concentration was assayed by triplicate. Cytotoxicity effect 
of compounds was defined as the 50% reduction of cell 
viability of treated culture cells with respect to untreated 
culture (CC50). 
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